Prinaberel (ERB-041) is an effective and selective ERβ agonist and >200-fold selective for ERβ.

Treatment with ERβ selective estrogen agonists liquiritigenin and ERB-041 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus [1]. Pretreatment the PMs with ERB-041 resulted in significant inhibition of LPS-induced iNOS expression and NF-kappaB activation by preventing its nuclear translocation [3].

Tumor numbers and volume were reduced by 60% and 84%, respectively, in the Erb-041-treated group as compared with UVB (alone) control. This inhibition in tumorigenesis was accompanied by a decrease in proliferating cell nuclear antigen (PCNA), cyclin D1, VEGF, and CD31, and an increase in apoptosis [2].

524684-52-4

C15H10FNO3

271.24

ERB 041;普林贝瑞

DMSO:38 mg/mL (140.1 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years